The first oral antiviral drug for individuals with mild to moderate COVID-19 is Cipmolnu 200 Capsule. It lessens the viral load and severity of the illness by stopping the virus from proliferating. On December 28, 2021, Indian drug regulatory authorities approved the medication for use in emergencies.
Patients with mild to moderate COVID-19 symptoms who are at high risk of developing severe symptoms should only use Cipmolnu 200 Capsule. Obesity, advanced age (>60), diabetes mellitus, and heart disease are among the risk factors. It is not recommended for patients with COVID-19 who need to be admitted to the hospital right away. The FDA in the United States and the UK regulatory body have both approved this medication for use in emergencies.
Cipmolnu 200 Capsule must be taken orally for a maximum of five days in a row. Even if you start to feel better, it’s crucial to finish the full five days of treatment, so keep taking it. Some people may experience nausea, headaches, diarrhoea, and dizziness with the medication. Talk to the doctor about any such side effects you encounter. They might offer advice on how to avoid them or assist with treatment.
In order to avoid taking Cipmolnu 200 Capsule, inform your doctor of any past medical issues. Tell your doctor about all the other medications you take so they can ensure it’s safe for you. Cipmolnu 200 Capsule usage is not advised for expectant mothers. Before taking this medication, women who are pregnant or nursing should speak with their doctors.
Uses of Cipmolnu Capsule
Treatment for COVID-19, a mild to moderate coronavirus condition.
There are no reviews yet.